restructuring
Immunovia to Restructure Operations, Lay Off Employees
The firm said it will stop commercialization of its ImmRay PanCan-d test in the US to focus on developing its next-generation pancreatic cancer detection test.
DermTech to Cut 15 Percent of Workforce in Restructuring to Focus on Skin Cancer Test
The San Diego-based company said it will halt its pipeline programs in order to focus on growing volume and reimbursement for its noninvasive melanoma DNA test.
T2 Biosystems Lays off 30 Percent of Workforce as Q1 Revenues Drop 71 Percent
The company also announced that it has submitted its T2Biothreat Panel to the US Food and Drug Administration for 510(k) clearance.
LumiraDx to Lay off 40 Percent of Workforce in Cost Restructuring Plan
The cost restructuring program is expected to result in about $36 million in yearly savings, with the majority of savings realized in the next four months.
InfanDx Restructures After Halting Development of Hypoxic-Ischemic Encephalopathy Test
An in-depth analysis of biomarker validation study results for the firm's hypoxic-ischemic encephalopathy early detection tests raised doubts about its generalizability.